BBI - Brickell Biotech changes name to Fresh Tracks Therapeutics

• Clinical-stage biotech Brickell Biotech, Inc. ( NASDAQ: BBI ) announced a major rebranding exercise on Wednesday, renaming its corporate identity to Fresh Tracks Therapeutics, Inc.
• Accordingly, the company said that BBI’s name, logo, website, and branding would change to reflect the company’s new strategic shift towards autoimmune, inflammatory, and other diseases.
• In line with the rebranding, the company’s common stock will begin trading under the new Nasdaq ticker symbol “FRTX” from Thursday.
• Meanwhile, in connection with the rebranding, the company has formed a Scientific Advisory Board (SAB), which comprises experts in immunology and inflammation.
• SAB will guide the management and board as the company targets autoimmune and inflammatory diseases with early-stage candidate FRTX-02, pre-clinical asset FRTX-10, and the next-generation kinase inhibitor platform.
• FRTX-02, formerly known as BBI-02, is undergoing a Phase 1 trial for atopic dermatitis with topline data expected in early 2023.

For further details see: